213 related articles for article (PubMed ID: 22606044)
1. Donepezil combined with natural hirudin improves the clinical symptoms of patients with mild-to-moderate Alzheimer's disease: a 20-week open-label pilot study.
Li DQ; Zhou YP; Yang H
Int J Med Sci; 2012; 9(3):248-55. PubMed ID: 22606044
[TBL] [Abstract][Full Text] [Related]
2. Donepezil for dementia due to Alzheimer's disease.
Birks JS; Harvey RJ
Cochrane Database Syst Rev; 2018 Jun; 6(6):CD001190. PubMed ID: 29923184
[TBL] [Abstract][Full Text] [Related]
3. Donepezil in Alzheimer's disease: eighteen month results from Southampton Memory Clinic.
Matthews HP; Korbey J; Wilkinson DG; Rowden J
Int J Geriatr Psychiatry; 2000 Aug; 15(8):713-20. PubMed ID: 10960883
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of donepezil in patients with Alzheimer's disease: results of a global, multinational, clinical experience study.
Boada-Rovira M; Brodaty H; Cras P; Baloyannis S; Emre M; Zhang R; Bahra R;
Drugs Aging; 2004; 21(1):43-53. PubMed ID: 14715043
[TBL] [Abstract][Full Text] [Related]
5. Functional, cognitive and behavioral effects of donepezil in patients with moderate Alzheimer's disease.
Gauthier S; Feldman H; Hecker J; Vellas B; Emir B; Subbiah P;
Curr Med Res Opin; 2002; 18(6):347-54. PubMed ID: 12442882
[TBL] [Abstract][Full Text] [Related]
6. Donepezil for vascular cognitive impairment.
Malouf R; Birks J
Cochrane Database Syst Rev; 2004; (1):CD004395. PubMed ID: 14974068
[TBL] [Abstract][Full Text] [Related]
7. Assessing therapeutic efficacy in a progressive disease: a study of donepezil in Alzheimer's disease.
Johannsen P; Salmon E; Hampel H; Xu Y; Richardson S; Qvitzau S; Schindler R;
CNS Drugs; 2006; 20(4):311-25. PubMed ID: 16599649
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of donepezil in the treatment of neuropsychiatric symptoms in Alzheimer disease.
Holmes C; Wilkinson D; Dean C; Vethanayagam S; Olivieri S; Langley A; Pandita-Gunawardena ND; Hogg F; Clare C; Damms J
Neurology; 2004 Jul; 63(2):214-9. PubMed ID: 15277611
[TBL] [Abstract][Full Text] [Related]
9. A multinational, randomised, 12-week study comparing the effects of donepezil and galantamine in patients with mild to moderate Alzheimer's disease.
Jones RW; Soininen H; Hager K; Aarsland D; Passmore P; Murthy A; Zhang R; Bahra R
Int J Geriatr Psychiatry; 2004 Jan; 19(1):58-67. PubMed ID: 14716700
[TBL] [Abstract][Full Text] [Related]
10. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. Donepezil Study Group.
Rogers SL; Doody RS; Mohs RC; Friedhoff LT
Arch Intern Med; 1998 May; 158(9):1021-31. PubMed ID: 9588436
[TBL] [Abstract][Full Text] [Related]
11. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results.
Amenta F; Carotenuto A; Fasanaro AM; Rea R; Traini E
J Neurol Sci; 2012 Nov; 322(1-2):96-101. PubMed ID: 22959283
[TBL] [Abstract][Full Text] [Related]
12. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
[TBL] [Abstract][Full Text] [Related]
13. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Down syndrome and Alzheimer's disease--pilot study.
Prasher VP; Huxley A; Haque MS;
Int J Geriatr Psychiatry; 2002 Mar; 17(3):270-8. PubMed ID: 11921156
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of donepezil over 3 years: an open-label, multicentre study in patients with Alzheimer's disease.
Burns A; Gauthier S; Perdomo C
Int J Geriatr Psychiatry; 2007 Aug; 22(8):806-12. PubMed ID: 17199235
[TBL] [Abstract][Full Text] [Related]
15. A long-term comparison of galantamine and donepezil in the treatment of Alzheimer's disease.
Wilcock G; Howe I; Coles H; Lilienfeld S; Truyen L; Zhu Y; Bullock R; Kershaw P;
Drugs Aging; 2003; 20(10):777-89. PubMed ID: 12875613
[TBL] [Abstract][Full Text] [Related]
16. Safety and tolerability of donepezil at doses up to 20 mg/day: results from a pilot study in patients with Alzheimer's disease.
Doody RS; Corey-Bloom J; Zhang R; Li H; Ieni J; Schindler R
Drugs Aging; 2008; 25(2):163-74. PubMed ID: 18257603
[TBL] [Abstract][Full Text] [Related]
17. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: final analysis of a US multicentre open-label study.
Rogers SL; Doody RS; Pratt RD; Ieni JR
Eur Neuropsychopharmacol; 2000 May; 10(3):195-203. PubMed ID: 10793322
[TBL] [Abstract][Full Text] [Related]
18. Donepezil for dementia due to Alzheimer's disease.
Birks JS; Harvey R
Cochrane Database Syst Rev; 2003; (3):CD001190. PubMed ID: 12917900
[TBL] [Abstract][Full Text] [Related]
19. Donepezil for dementia due to Alzheimer's disease.
Birks J; Harvey RJ
Cochrane Database Syst Rev; 2006 Jan; (1):CD001190. PubMed ID: 16437430
[TBL] [Abstract][Full Text] [Related]
20. The clinical meaningfulness of ADAS-Cog changes in Alzheimer's disease patients treated with donepezil in an open-label trial.
Rockwood K; Fay S; Gorman M; Carver D; Graham JE
BMC Neurol; 2007 Aug; 7():26. PubMed ID: 17760991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
